Novartis AG’s Sandoz division struck a deal with Taiwan’s EirGenix Inc. to market a biosimilar version of Roche’s Herceptin that is in late-stage development to treat some cancer tumors.

OncoSec Medical Incorporated and Duke University School of Medicine announced that they have entered into a collaborative research agreement to evaluate the use of OncoSec’s proprietary Tavoplus (enhanced IL-12 DNA-plasmid) in combination or sequence with a HER2-plasmid vaccine administered with OncoSec’s novel intratumoral delivery system.